# A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)

Study · id `cardio:ct-nct03175120` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03175120](<https://clinicaltrials.gov/study/NCT03175120>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03175120

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 453 participants.

## Technical summary

Registry record NCT03175120. Randomized; double masking; primary purpose treatment. Start 2017-05-26 (actual); primary completion 2019-03-05 (actual). Results posted on 2020-03-19.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 453 participants (enrolled count; ClinicalTrials.gov record NCT03175120, source copy `cardio:ctgov-nct03175120-2020-03-19`, retrieved 2026-10-26)
- Started: 2017-05-26 (actual) (ClinicalTrials.gov record NCT03175120, source copy `cardio:ctgov-nct03175120-2020-03-19`, retrieved 2026-10-26)
- Primary completion: 2019-03-05 (actual) (ClinicalTrials.gov record NCT03175120, source copy `cardio:ctgov-nct03175120-2020-03-19`, retrieved 2026-10-26)
- Completion: 2019-04-04 (actual) (ClinicalTrials.gov record NCT03175120, source copy `cardio:ctgov-nct03175120-2020-03-19`, retrieved 2026-10-26)
- Results first posted: 2020-03-19 (ClinicalTrials.gov record NCT03175120, source copy `cardio:ctgov-nct03175120-2020-03-19`, retrieved 2026-10-26)
- Countries: China; Hong Kong SAR China (ClinicalTrials.gov record NCT03175120, source copy `cardio:ctgov-nct03175120-2020-03-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03175120-2020-03-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
- Acronym: DUAL™ II China
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Insulin degludec/liraglutide
- Intervention (Drug): Insulin degludec
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 4b87940a4791f5b7d094c728c87245a6d3689951d69a084ab4fc73f8285e5300
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
